BioNTech SE (NASDAQ:BNTX) was down sharply on Tuesday after issuing weaker‑than‑expected 2026 revenue guidance as Covid vaccine sales normalize and outlining a capital‑intensive pivot toward oncology.
- BNTX stock is sinking. See the chart and price action here.
The company’s co-founders Ugur Sahin and Ozlem Tureci plan to transition out by the end of 2026 to launch a new mRNA‑focused firm, creating a combination that is pressuring near‑term earnings expectations and unsettling some investors about the transition phase.
Covid Vaccine Sales Down
The company guided 2026 total revenue to roughly $2.2–$2.5 billion, below Street expectations, stating that Covid will be a smaller contributor going forward and growth will depend increasingly on the oncology pipeline.
CFO Ramon Zapata emphasized on the earnings call that “for COVID-19, we continue to see a stable position with a strong market share and stable pricing,” but also …